Gyre Therapeutics, Inc.

GYRE Healthcare Biotechnology

In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.

6.08 0.32 −5.00%
Market cap
$678.6M
P/E
0.0×
Fwd P/E
−21.7×
Dividend yield
—
F-score
4/9
Altman Z
16.83
Beneish M
−2.02
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 141.20 106.57

+8 more quarters

P/S ratio
5.70 5.44 5.41 6.15
P/FCF ratio
0.00 207.39 0.00 450.03
P/Operating CF
(39.65) 200.15 (112.14) 47.60
P/B ratio
4.65 4.65 10.59 4.93
EV/Sales
5.10 5.06 4.66 5.65
EV/EBITDA
0.00 235.25 38.79 62.60
EV/FCF
(83.33) 192.86 (615.37) 413.62
Current Ratio
4.26 4.64 6.28 6.19
Net Debt/EBITDA
5.80 5.74 (17.74) (8.28)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(3.03%) (1.15%) 0.71% 0.94%
Free Cash Flow Yield
(1.07%) 0.48% (0.14%) 0.22%
Free Cash Flow per Share
(0.18) 0.03 (0.06) 0.15
Book value per Share
1.64 1.50 2.11 1.51
Free Cash Flow
(18.01) 3.00 (5.75) 13.63
EV/EBIT
0.00 0.00 47.30 81.69
Other line items

Show all line items

Columns are period end dates